SecSonar.com

Novo Nordisk A/S (NVO)

Novo Nordisk A/S at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Novo Nordisk A/S (NVO) is a Biotechnology company based in DK with a market capitalization of $202.7B. Revenue grew 6.4% year-over-year and the company generated $4.4B in free cash flow. This page tracks NVO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

DK · 77.41K employees · IPO Apr 30, 1981

Valuation

Valuation & price

$44.74 · as of May 17, 2026 · -37.6% vs 52w high

1.9

P/E ratio

Latest-FY diluted EPS

1.04

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$71.70$53.87$36.04Jul 25Dec 25Jul 26Jul 7, 25$69.32Jul 9, 25$69.69Jul 11, 25$68.93Jul 15, 25$67.22Jul 17, 25$65.29Jul 21, 25$64.92Jul 23, 25$70.03Jul 25, 25$71.70Jul 29, 25$53.94Jul 31, 25$47.07Aug 4, 25$48.81Aug 6, 25$45.38Aug 11, 25$49.87Aug 13, 25$50.90Aug 15, 25$52.41Aug 19, 25$54.78Aug 21, 25$55.45Aug 25, 25$56.34Aug 27, 25$56.44Aug 29, 25$56.46Sep 3, 25$56.74Sep 5, 25$55.23Sep 9, 25$54.30Sep 11, 25$54.30Sep 16, 25$57.20Sep 18, 25$61.85Sep 22, 25$60.71Sep 24, 25$58.74Sep 26, 25$55.61Sep 30, 25$55.49Oct 2, 25$58.74Oct 6, 25$59.65Oct 8, 25$59.61Oct 10, 25$56.93Oct 14, 25$56.66Oct 16, 25$56.09Oct 21, 25$54.78Oct 23, 25$53.23Oct 27, 25$52.89Oct 29, 25$51.37Oct 31, 25$49.46Nov 4, 25$48.25Nov 6, 25$46.51Nov 10, 25$45.94Nov 12, 25$50.26Nov 14, 25$48.26Nov 18, 25$47.55Nov 20, 25$47.60Nov 25, 25$47.06Nov 28, 25$49.35Dec 2, 25$47.43Dec 4, 25$47.99Dec 8, 25$46.77Dec 10, 25$49.05Dec 12, 25$50.18Dec 16, 25$48.96Dec 18, 25$47.61Dec 22, 25$48.10Dec 24, 25$52.56Dec 29, 25$51.47Jan 2, 26$52.39Jan 6, 26$56.26Jan 8, 26$57.34Jan 12, 26$59.86Jan 14, 26$58.91Jan 16, 26$62.33Jan 21, 26$59.32Jan 23, 26$62.26Jan 27, 26$62.89Jan 29, 26$59.33Feb 2, 26$58.93Feb 4, 26$47.19Feb 9, 26$49.37Feb 11, 26$48.74Feb 13, 26$49.57Feb 18, 26$49.23Feb 20, 26$47.42Feb 24, 26$38.59Feb 26, 26$37.62Mar 2, 26$37.76Mar 4, 26$38.50Mar 6, 26$38.58Mar 10, 26$38.72Mar 12, 26$38.02Mar 17, 26$38.43Mar 19, 26$37.08Mar 23, 26$36.82Mar 25, 26$36.33Mar 27, 26$36.04Mar 31, 26$36.75Apr 2, 26$36.98Apr 7, 26$36.91Apr 9, 26$37.44Apr 13, 26$37.98Apr 15, 26$40.81Apr 17, 26$40.52Apr 22, 26$39.15Apr 24, 26$41.17Apr 28, 26$41.17Apr 30, 26$42.22May 4, 26$44.39May 6, 26$45.76May 8, 26$46.07May 12, 26$47.00May 14, 26$45.80May 18, 26$44.28May 20, 26$45.07May 22, 26$44.96May 28, 26$45.51Jun 1, 26$44.07Jun 3, 26$42.00Jun 5, 26$42.96Jun 9, 26$42.19Jun 11, 26$43.96Jun 15, 26$43.92Jun 17, 26$43.52Jun 22, 26$45.88Jun 24, 26$47.41Jun 26, 26$48.07Jul 2, 26$50.43
$35.2952-week range$71.70
Loading valuation history…

Fundamentals

Key fundamentals

$202.7B

Market cap

6.4%

Revenue growth (YoY)

81.0%

Gross margin

$4.4B

Free cash flow (USD)

$104B

Net debt

-0.1%

Share dilution

4/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$111.8BFY 2017$111.7BFY 2018$111.8BFY 2019$122.0BFY 2020$126.9BFY 2021$140.8BFY 2022$177.0BFY 2023$232.3BFY 2024$290.4BFY 2025$309.1B
$111.8B$309.1B

Free cash flow by year

2016 → 2025

FY 2016$40.0BFY 2017$32.5BFY 2018$32.2BFY 2019$35.6BFY 2020$29.9BFY 2021$47.6BFY 2022$64.1BFY 2023$70.0BFY 2024$69.7BFY 2025$29.0B
$40B$29B

Gross margin by year

2021 → 2025

FY 202183.2%FY 202283.9%FY 202384.6%FY 202484.7%FY 202581.0%
83.2%81.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed May 22, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingShare Repurchase ProgrammeJun 29, 2026Filing
  • 6-K filingShare Repurchase ProgrammeJun 24, 2026Filing
  • 6-K filingShare Repurchase ProgrammeJun 15, 2026Filing
  • 6-K filingShare Repurchase ProgrammeJun 8, 2026Filing
  • 6-K filingShare Repurchase ProgrammeJun 1, 2026Filing
  • 6-K filingShare Repurchase ProgrammeMay 27, 2026Filing
  • 6-K filingRegulatory UpdateMay 22, 2026Filing
  • Annual reportAnnual Report FiledMay 22, 2026Filing
  • 6-K filingShare Repurchase ProgrammeMay 18, 2026Filing
  • 6-K filingTrading NotificationMay 13, 2026Filing

Questions

Frequently asked questions

What is Novo Nordisk A/S's market cap?

Novo Nordisk A/S (NVO) has a market capitalization of $202.7B.

What is NVO's P/E ratio?

NVO trades at a price-to-earnings ratio of 1.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is NVO's price-to-book (P/B) ratio?

NVO trades at 1.04 times book value per share.

Are insiders buying NVO stock?

SEC Form 4 filings show no open-market insider buys at Novo Nordisk A/S in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

VRTX

Vertex Pharmaceuticals Incorporated

$113.6B

REGN

Regeneron Pharmaceuticals, Inc.

$63.5B

ARGX

argenx SE

$51.7B

ALNY

Alnylam Pharmaceuticals, Inc.

$40.3B

RVMD

Revolution Medicines, Inc.

$33.3B

RPRX

Royalty Pharma plc

$23.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.